Restructuring Costs

9 Months Ended

Sep. 30, 2016

Restructuring Costs [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

10. Restructuring Costs

The Company terminated the PROCEED trial in May 2014 after the interim futility analysis indicated that vintafolide did not demonstrate efficacy on the pre-specified outcome of progression-free survival for the treatment of platinum-resistant ovarian cancer. As a result, the Company recorded a charge of $4.1 million for remaining expenses of the PROCEED trial, including site close-out expenses, in the year ended December 31, 2014. At September 30, 2016, the Company had a clinical trial accrual balance related to the PROCEED trial termination of $17,800, which is expected to be fully paid in the fourth quarter of 2016.

The following table summarizes the restructuring accruals for the three and nine months ended September 30, 2016:

	PROCEED
	Trial
	Termination
	Accrual
Balance at June 30, 2016	$	23,600
Amounts paid in the three months ended September 30, 2016		(5,800)
Balance, September 30, 2016	$	17,800

	PROCEED
	Trial
	Termination
	Accrual
Balance, December 31, 2015	$	46,600
Amounts paid in the nine months ended September 30, 2016		(28,800)
Balance, September 30, 2016	$	17,800